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Background/aims: To evaluate retrospectively the clinical outcomes of patients presenting 
with submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration 
(nAMD), treated by vitrectomy, submacular tissue plasminogen activator (tPA) injection and pneu-
matic displacement of SMH with air followed by postoperative intravitreal ranibizumab (RZB).
Methods: Patients with SMH and nAMD had 25-guage vitrectomy and subretinal tPA 
(12.5 micrograms/0.1 mL) with fluid/air exchange. Intravitreal RZB was administered postop-
eratively to patients eligible for National Health Service (NHS) funded treatment.
Results: Of the total of 16 patients, 11 (68.7%) had complete displacement of SMH. The remain-
ing five had residual SMH, mainly subretinal pigment epithelium in location. Three of the four 
patients who previously had a failed expansile gas pneumatic displacement were successfully 
displaced with vitrectomy surgery. At presentation 5/16 (31.3%) patients were eligible for NHS 
funded intravitreal RZB. This increased to 12 patients after the vitrectomy procedure (75.0%). 
At 6 months postoperatively all improved by $1 line. Ten of the 16 patients (63%) improved 
by $2 lines, with 10 of the 12 patients (83%) treated with RZB improving by $2 lines.
Conclusion: Vitrectomy/subretinal tPA/air to displace SMH followed by intravitreal RZB 
injection can stabilize/improve vision in patients with nAMD. This technique displaces hemor-
rhage not displaced by attempted expansile gas techniques.
Keywords: submacular hemorrhage, neovascular age-related macular degeneration, vitrectomy, 
tissue plasminogen activator, ranibizumab
Introduction
Patients with submacular hemorrhage (SMH) associated with neovascular age-related 
macular degeneration (nAMD) generally have a poor visual prognosis.1–4 This is thought 
to be due to physical separation of the retinal pigment epithelium (RPE) from the retina, 
shear stress on the photoreceptors from fibrin retraction and iron related toxicity to the 
RPE and choriocapillaris.5,6 Treatment with vascular endothelial growth factor (VEGF) 
inhibitors has transformed the prognosis of nAMD, but in the past, patients with SMH 
were excluded from major clinical trials and evidence for their efficacy in these patients 
is lacking.7,8 Some patients with SMH in the UK are also excluded from National Health 
Service funded ranibizumab (RZB) treatment by visual eligibility criteria.9
Whilst surgical removal of SMH has been shown to be ineffective at preserving 
vision,10 two less traumatic techniques for displacing SMH away from the fovea have 
been described. The ‘expansile gas technique’   utilizes pneumatic displacement of SMH 
10060Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
638
Sandhu et al
by the intravitreal injection of expansile gas   combined with 
intravitreal tissue plasminogen activator (tPA) and face down-
ward posture postoperatively.11–17 An alternative technique, 
called here the ‘vitrectomy technique’, involves vitrectomy 
with subretinal tPA injection and air exchange.18,19
Studies have been published assessing the effectiveness 
of the expansile gas technique combined with anti-VEGF 
agents for preserving vision in nAMD associated with 
SMH.20–22 Advantages for the vitrectomy technique include 
a lesser requirement for posturing, better displacement of 
blood and less direct shear stress on photoreceptors because 
of direct hemorrhage lysis by subretinal tPA as compared 
to the expansile gas technique.18,19 Vitrectomized eyes may 
however be associated with altered pharmacokinetics of RZB 
with greater dissipation and therefore reduced effectiveness 
of the anti-VEGF action.
We have been treating patients presenting with large thick 
SMH associated with nAMD in patients who have posturing 
difficulty with vitrectomy and subretinal tPA followed by 
postoperative intravitreal RZB and carried out a retrospective 
analysis of our results.
Methods
Consecutive patients presenting to Sunderland Eye Infir-
mary, UK, between August 2007 and December 2008 with 
SMH secondary to nAMD, were treated with 25-gauge 
vitrectomy, subretinal tPA and air to displace SMH away 
from the foveal center. Patients were treated if the follow-
ing criteria were met: a clear history of suddenly reduced 
vision within 6 weeks; the presence of thick SMH involving 
the foveal center obscuring the RPE and choroidal patterns 
and appearing dark red or black with visible elevation; a 
total extent of blood of at least 3 disc diameters in greatest 
linear dimension; signs of nAMD in the effected eye and/
or in the fellow eye (drusen, pigmentary change or nAMD); 
patients were unable to comply with the postoperative face 
down posturing requirements of an expansile gas technique 
(ie, unable to maintain a face downward position for 48 
hours), or who had previously failed displacement using an 
expansile gas technique.
Patients with a vitreous hemorrhage obscuring the fundus 
were excluded as were patients with massive hemorrhage 
measuring more than 12 disc diameters in greatest linear 
dimension.
Vitrectomy was carried out using the Alcon Accurus® 
25 g system (Alcon Laboratories, Fort Worth, TX, USA). 
Core vitrectomy was performed, and if no posterior   vitreous 
  detachment was present, this was not induced unless 
  vitreomacular traction was present preoperatively (one 
patient). An existing posterior vitreous detachment was 
  present in eight patients. Subretinal tPA was injected at a 
concentration of 12.5 micrograms in 0.1 mL with a 41-gauge 
needle at 1–4 points over the surface of the SMH away from 
the fovea as previously described.18,19 Volumes injected ranged 
from 0.05 mL to 0.15 mL. Fluid/air exchange was performed 
at the end of surgery. No gas was exchanged. No specific 
posturing instructions were given for daytime but the patient 
was told to sleep with three pillows on the side of the effected 
eye at night. Seven patients were     pseudophacic at the time of 
vitrectomy surgery and a further 3 had cataract surgery dur-
ing the first year of follow up when they developed visually 
significant lens opacities. All surgery was carried out under 
local anesthesia by a single surgeon (DHWS).
Patients were reviewed 1 day and 1 week postoperatively. 
Visual acuity (VA) was assessed at the 1 week visit and 
0.05 mL of intravitreal RZB was given to all patients whose 
vision was logarithm of the minimum angle of resolution 
(logMAR) 1.20 (6/96) or better at 1 week following initial 
surgery. The RZB injection was then repeated at monthly 
intervals until 3 doses had been given. Further RZB was given 
depending on clinical response as per the National Institute 
for Health and Clinical Excellence (NICE)/Royal College of 
Ophthalmologist guidelines.23
At each visit, the patient underwent best-corrected Snel-
len best corrected visual acuity (BCVA) measurements. This 
was converted to and expressed as logMAR for subsequent 
analysis. Count fingers vision was recorded as logMAR 2 
and hand movements as logMAR 3. A biomicroscopic fun-
dus examination, color photography and optical coherence 
tomography (OCT) were carried out at each visit. The greatest 
linear dimension of SMH using disc diameters was assessed 
from preoperative photography. Success of the procedure in 
displacing hemorrhage away from the fovea at 1 week and 
BCVA at 1, 6 and 12 months were used as outcome measures. 
The numbers of intravitreal RZB injections in the 12 months 
of follow up were recorded.
Applicable institutional and governmental regulations 
were followed during this research. The study was classified 
as a service evaluation by the local ethics committee and as 
such did not require formal ethical approval.
Results
Of 16 patients presenting, and meeting the criteria, 10 were 
female patients. The mean age was 81 years (range: 76–88). 
The mean time from surgery to symptoms of reduced vision 
was 15 days (range: 3 days–6 weeks). Four patients had Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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a previously failed attempt at expansile gas displacement. 
Three other patients had a history of previous eye problems: 
superotemporal branch retinal vein occlusion (logMAR 
VA 0.48); macular hole surgery (logMAR 0.30); previous 
bevacizumab (BZB) injections prior to the onset of SMH 
(logMAR 0.48 prior to SMH).
Five of the 16 (31%) patients with SMH were eligible for 
intravitreal RZB based on vision criteria (logMAR 1.20 or 
better) at presentation. This increased to 12 patients after the 
displacement procedure (75%). Four patients did not receive 
intravitreal RZB as their vision did not improve to 6/96 or 
better after vitrectomy surgery.
Follow up was available on 16 patients at 1 and 6 months 
and 10 patients at 12 months (3 died and 3 were lost to fol-
low up).
Presenting logMAR VA ranged from 0.78 to 3.00 with a 
mean preoperative logMAR VA of 1.81 (95% confidence inter-
val [CI]: 1.38 to 2.24). Subgroup analysis of logMAR VA of 
those treated with RZB improved to 0.58 (95% CI: 0.43 to 0.74, 
when compared to baseline P , 0.001), 0.69 (95% CI: 0.46 to 
0.91, P , 0.001) and 0.66 (95% CI: 0.46 to 0.87, P = 0.001) 
at 1, 6 and 12 months postoperatively respectively, Figure 1. 
Subgroup analysis of logMAR VA of those not treated with 
RZB were not statistically different from baseline (P $ 0.10). 
There was no difference in age between those treated with RZB 
and those not (P = 0.50). However, there was a difference in 
duration of symptoms for those treated with RZB (10.7 days, 
95% CI: 7.4 to 13.9) and those not (28.3 days, 95% CI: 10.7 
to 45.8, P , 0.001). Median duration of symptoms was 12.5 
days. Those presenting with less duration than this had a trend 
for better a 12 month logMAR VA outcome than those pre-
senting later but was not statistically significant (0.58 vs 0.85, 
P = 0.19). At 6 months postoperatively 10 of the original 16 
patients (63%) had improved by $2 lines. Ten of the 12 patients 
(83%) treated with RZB improved by $2, and all improved 
by $1 line. The mean number of lines of improvement was 
3.4 at 6 months postoperatively.
The mean greatest linear diameter (GLD) of SMH was 
6 disc diameters (range: 3–12). In the 12 patients who were 
eligible for RZB after surgery, the mean GLD of SMH was 
5 disc diameters (range: 4–9). The four patients who were 
ineligible had a mean GLD of 8.5 disc diameters (range: 
6–12). Median GLD was 5.5. Those presenting with less 
GLD than this had a trend for better a 12 month logMAR VA 
outcome than those presenting later but was not statistically 
significant (0.59 vs 0.78, P = 0.34).
The mean number of RZB injections given to those with 
eligible VA after surgery was 3.7 injections at 6 months. 
At 12 months the mean number of injections was 4.5 
(range: 3–8).
Eleven of the 16 (69%) patients had complete displace-
ment of SMH. Five of the 16 (31%) patients had residual 
SMH which was mainly sub-RPE in location. In all patients 
treated with RZB after displacement, nAMD was evident on 
either slit lamp biomicroscopy or fluorescein angiography. 
Three of the four patients who previously had a failed pneu-
matic displacement were successfully displaced with vitrec-
tomy surgery. One of the 16 patients had a small foveal retinal 
dehiscence when injecting tPA. No patient had intraoperative 
retinal breaks or postoperative retinal detachments.
No patient experienced a significant vitreous   hemorrhage 
postoperatively, however 2 patients given RZB experienced 
a recurrent SMH postoperatively. One patient with a mild 
hemorrhage at 4 months was treated with further lucentis, 
the other had a major SMH at 2 months involving the entire 
temporal retina reducing the vision to perception of light. 
This patient was treated with 180-degree retinotomy, SMH 
removal and an RPE patch and regained vision to logMAR 
1.25 (initial vision logMAR 3.00, hand movements, vision 
after displacement, LogMAR 0.78).
Discussion
It is not uncommon for patients with nAMD to develop 
SMH that has a significantly worse visual prognosis.1–4 
In one study approximately 40% of patients with pigment 
epithelial detachments developed SMH during the course of 
their disease.24 Furthermore, treatment with VEGF inhibitors 
is possibly associated with an increased incidence of SMH 
in certain subtypes of nAMD.25 In a study by Goverdhan 
and Lochhead, 40% of patients with large occult choroidal 
neovascularization (CNV) developed SMH after treatment 
with BZB.26 Unfortunately patients with SMH were excluded 
from all the recent major anti-VEGF trials and the manage-
ment of such patients is therefore not guided by randomized 
controlled trial evidence.7,8 Indeed, there is no consensus 
regarding optimal treatment in patients with SMH associ-
ated with nAMD.
One of the arms of the large submacular surgery trials 
carried out in the USA in the 1990s evaluated the efficacy of 
removing SMH with vitrectomy surgery. Unfortunately the 
procedure did not improve the visual outcomes compared 
to observation alone, probably for two main reasons. Firstly, 
direct surgical removal of hemorrhage resulted in retinal and 
RPE trauma, and secondly no treatment was given for the 
underlying choroidal neovascular membrane (CNVM). There 
was also a high postoperative retinal detachment rate.10Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Techniques have subsequently been described to pneu-
matically displace SMH from the foveal area, without actual 
removal. The most widespread technique described is using 
an intravitreally injected expansile bubble of gas combined 
with clot lysis using intravitreally injected tPA (‘expansile 
gas displacement’).11–17 Several papers have evaluated the 
efficacy of this relatively simple technique and described 
high success rates in terms of SMH displacement.12–17 Visual 
acuity improved in the short term but not longer because of 
the effect of recurrent CNVM growth.14 Clinicians are now 
starting to use these techniques combined with anti-VEGF 
to treat the underlying CNVM.20–22 Meyer et al20 described a 
series of 19 eyes who were treated with ‘expansile displace-
ment’ and BZB. They reported a mean visual acuity improve-
ment of 3.7 lines by 12 weeks postoperatively and successful 
displacement of the SMH in 17 of the 19 patients.
The treatment protocol carried out in our series for this 
particular group of patients resulted in a sustained improve-
ment in vision in 12 of the 16 patients. The technique of 
vitrectomy, subretinal tPA and air was effective in completely 
displacing SMH away from the fovea in 69% of the patients 
despite no specific daytime posturing instructions being given 
in a selected group of patients who were unable to comply 
with strict posturing requirements. It was also effective in 
3 patients who had a previously failed expansile gas pro-
cedure. The mean age of the patients treated was 81 years 
and highlights the difficulty of posturing in older patients 
who often have multiple health problems. Lincoff et al have 
recently demonstrated that optimum displacement of SMH 
after expansile gas displacement is achieved with only a 
40 degree forward face tilt downwards, with full face down 
positioning not needed.27 However, even this position can be 
arduous for elderly patients to maintain.
The effectiveness of the vitrectomy technique compared 
to an expansile gas technique in patients who can posture is 
unknown but it has been suggested that the former results in 
less shear stress on photoreceptors because of direct hemor-
rhage lysis by subretinal tPA prior to displacement as compared 
to intravitreally injected tPA with limited transretinal diffusion 
ability.28,29 Furthermore, a recent study showed vitrectomy and 
gas with subretinal tPA was more effective at displacing SMH 
than vitrectomy and gas with intravitreal tPA, suggesting the 
former effectively lyses clot.30 It is also possible vitrectomy 
may have other advantages in the treatment of nAMD. Previ-
ous authors have noted an association between nAMD and 
vitreous attachment with the presence of occult vitreomacular 
traction on OCT.31,32 Vitreoretinal separation induced either 
at the time of surgery or postoperatively may have a positive 
effect on retinal function. It is also possible the increased retinal 
oxygenation present after vitrectomy may have a positive effect 
on the course of nAMD.33,34 Conversely, vitrectomy can alter 
the pharmacokinetics of intravitreally injected drugs, reducing 
their half life and hence potentially reducing their effective-
ness.35,36 For this reason we deliberately limited the amount of 
vitrectomy and only induced a posterior vitreous detachment 
when vitreomacular traction was present on OCT preopera-
tively. Recently the use of subretinal BZB has been described 
with the vitrectomy technique to increase the efficacy of the 
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initial dose of the anti-VEGF.37 Subsequent doses still have to 
be given intravitreally however and the intravitreal RZB we 
used still appeared to be effective in controlling CNVM associ-
ated retinal dysfunction and scarring. We had no patients who 
had recurrent SMH before their first injection but 2 patients 
developed SMH later. It is uncertain whether this relates to the 
vitrectomy procedure reducing the efficacy of the RZB. SMH 
has been described after nonvitrectomized patients treated 
with anti-VEGFs25,26 and both RZB and BZB have been impli-
cated.38,39 In all patients, where displacement was effective and 
accurate postdisplacement fundus assessment was possible, 
there were signs of active nAMD present. This contrasts with 
previous reports of patients presenting with AMD associated 
SMH where no CNVM were found after displacement, perhaps 
relating to the selected study population.
The vitrectomy technique used did not displace SMH 
in all patients, particularly those with extensive sub-RPE 
hemorrhage, as opposed to subretinal, and patients who 
appeared to have significant amounts of older SMH despite 
a short history of reduced vision. Furthermore previous 
studies have suggested the best visual results are obtained in 
patients with SMH of less than 1–2 weeks duration even if 
the surgery is successful in terms of moving blood away from 
the fovea.17 There are also many other potential problems, 
as with any technique of hemorrhage displacement. SMH 
situated mainly superior to the fovea could potentially be 
made worse by inferior displacement. Recurrent SMH can 
occur.18,19,40 There can be retinotoxic effects from tPA.41–43 
Postoperative complications such as vitreous hemorrhage 
(8%) or retinal detachment (3%) can also occur.40
An important question therefore is: how does the tech-
nique of hemorrhage displacement followed by anti-VEGF 
compare to treatment with anti-VEGF alone? This has been 
described in case series with results better than the natural 
history.44,45 In particular, Stifter et al describe 21 eyes with 
SMH treated with BZB alone.45 At 4 months follow up, 71% 
of the eyes had visual acuity within 1 line of baseline or better, 
with 38% improving by at least 1 line. Sacu et al describe a 
retrospective series of patients with SMH (n = 20) treated 
with expansile gas displacement combined with anti-VEGF 
treatment and compared them to a series of patients (n = 10) 
who refused gas injection and were treated with anti-VEGF 
therapy alone.21 At 4 months, they found with expansile gas 
displacement, visual acuity improved in 80% compared to 
60% in the anti-VEGF alone treatment group.
In conclusion, vitrectomy with subretinal tPA and air to 
displace SMH followed by intravitreal RZB can improve 
vision and lead to regression of CNVM in patients with 
nAMD. The technique can displace hemorrhage which has 
not been displaced previously by pneumatic gas displacement 
techniques but does not displace sub-RPE or old hemorrhage. 
Our results compare favorably to natural history studies and 
patients treated with anti-VEGF agents alone, and are com-
parable to those treated with expansile gas displacement and 
anti-VEGF agents. Randomized controlled trials however are 
required to determine the optimum management of patients 
presenting with SMH secondary to nAMD.
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